EUVIMEDEUVIMED entdecken
Crossref

Stability and Activity of Interferon Beta to Treat Idiopathic Pulmonary Fibrosis with Different Nebulizer Technologies

Edgar Hernan Cuevas Brun, Zuo-Yi Hong, Yuan-Ming Hsu, Ciou-Ting Wang, Dai-Jung Chung, Shang-Kok Ng, Yau-Hsuan Lee, Tzu-Tang Wei iD

Journal of Aerosol Medicine and Pulmonary Drug Delivery · 2023

DOI: 10.1089/jamp.2022.0020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2023. Verfasst von Edgar Hernan Cuevas Brun und 7 weiteren Autor:innen. Beteiligte Einrichtung: HCmed Innovations Co., Ltd., Taipei, Taiwan. Hauptthemen laut MEDLINE: Interferon-beta, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Idiopathic pulmonary fibrosis (IPF) is a serious lung disease characterized by lung scarring, which results in breathing difficulty. Currently, patients with IPF exhibit a poor survival rate and have access to very limited therapeutic options. Interferon beta (IFN-β) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsing forms of multiple sclerosis, and it has also been shown to exhibit therapeutic potential in IPF. However, clinical use of IFN-β did not lead to improved overall survival in IPF patients in existing studies. One possibility is the limited efficiency of IFN-β delivery through intravenous or subcutaneous injection. Materials and Methods: The aerosol particle size distribution was determined with a laser diffraction particle size analyzer to characterize the droplet size and fine particle fraction generated by three types of nebulizers: jet, ultrasonic, and mesh. A breathing simulator was used to assess the delivery efficiency of IFN-β, and the temperature in the medication reservoirs was monitored with a thermocouple during nebulization. To further evaluate the antifibrotic activity of IFN-β pre- and postnebulization, bleomycin (BLM)- or transforming growth factor-beta (TGF-β)-treated human lung fibroblast (HLF) cells were used. Cell viability was measured by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Transwell migration assay and Q-PCR analysis were used to evaluate cell migration and the myofibroblast differentiation ability, respectively. IFN-β protein samples were prepared using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample loading buffer, and the expression of IFN-β was assessed by western blotting.

Results

Among the current drug delivery systems, aerosolized medication has shown increased efficacy of drug delivery for treating respiratory diseases when compared with parenteral drugs. It was found that neither the structural integrity nor the biological function of nebulized IFN-β was compromised by the nebulization process of the mesh nebulizer. In addition, in BLM dose-response or TGF-β-induced lung fibroblast proliferation assays, these effects could be reversed by both parenteral and inhaled IFN-β nebulized with the mesh nebulizer. Nebulized IFN-β with the mesh nebulizer also significantly inhibited the migration and myofibroblast differentiation ability of TGF-β-treated HLF cells.

Conclusions

The investigations revealed the potential efficacy of IFN-β in the treatment of IPF with the mesh nebulizer, demonstrating the higher efficiency of IFN-β delivered through the mesh nebulizer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interferon-betaIdiopathic Pulmonary FibrosisHumansAdministration, InhalationRespiratory Aerosols and DropletsNebulizers and VaporizersDrug Delivery SystemsTransforming Growth Factor betaParticle Size

Stichwörter der Autor:innen

human lung fibroblast (HLF)idiopathic pulmonary fibrosisinterferon beta (IFN-β)mesh nebulizer

Substanzen

Interferon-betaTransforming Growth Factor beta

Autor:innen und Institutionen

  • HCmed Innovations Co., Ltd., Taipei, Taiwan.
  • Department and Graduate Institute of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Chemical Biology and Molecular Biophysics, Taiwan International Graduate Program in Chemical Biology and Molecular Biophysics (TIGP-CBMB), Academia Sinica, Taipei, Taiwan.

ORCID-Profile: Tzu-Tang Wei

Zitieren

APA

Brun, E. H. C., Hong, Z. Y., Hsu, Y. M., Wang, C. T., Chung, D. J., Ng, S. K., Lee, Y. H., & Wei, T. T. (2023). Stability and Activity of Interferon Beta to Treat Idiopathic Pulmonary Fibrosis with Different Nebulizer Technologies. Journal of Aerosol Medicine and Pulmonary Drug Delivery. https://doi.org/10.1089/jamp.2022.0020

Vancouver

Brun EHC, Hong ZY, Hsu YM, Wang CT, Chung DJ, Ng SK, et al. Stability and Activity of Interferon Beta to Treat Idiopathic Pulmonary Fibrosis with Different Nebulizer Technologies. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2023. doi:10.1089/jamp.2022.0020

BibTeX
@article{Brun2023,
  author = {Brun, Edgar Hernan Cuevas and Hong, Zuo-Yi and Hsu, Yuan-Ming and Wang, Ciou-Ting and Chung, Dai-Jung and Ng, Shang-Kok and Lee, Yau-Hsuan and Wei, Tzu-Tang},
  title = {Stability and Activity of Interferon Beta to Treat Idiopathic Pulmonary Fibrosis with Different Nebulizer Technologies},
  journal = {Journal of Aerosol Medicine and Pulmonary Drug Delivery},
  year = {2023},
  doi = {10.1089/jamp.2022.0020}
}
Kostenlos starten →